Search results
Results From The WOW.Com Content Network
Danoprevir is a clinical candidate based on its favorable potency profile against multiple HCV genotypes 1–6 and key mutants (GT1b, IC 50 = 0.2–0.4 nM; replicon GT1b, EC 50 = 1.6 nM). [4] Danoprevir has been evaluated in an open-label, single arm clinical trial in combination with ritonavir for treating COVID-19 [ 5 ] and favourably ...
Protease inhibitors can cause a syndrome of lipodystrophy, hyperlipidemia, diabetes mellitus type 2, and kidney stones. [14] This lipodystrophy is colloquially known as "Crix belly", after indinavir (Crixivan). [15]
Boceprevir (INN, trade name Victrelis) is a protease inhibitor used to treat hepatitis caused by hepatitis C virus (HCV) genotype 1. [2] [3] It binds to the HCV nonstructural protein 3 active site. [4] It was initially developed by Schering-Plough, [5] then by Merck after it acquired Schering in 2009. It was approved by the FDA in May 2011. [6]
Cure rates are 94% to 99% in people infected with hepatitis C virus (HCV) genotype 1. [9] Some evidence also supports use in HCV genotype 3 and 4. [9] It is taken daily by mouth for 8–24 weeks. [8] It is generally well tolerated. [10] Common side effects include muscle pains, headache, nausea, rash, and cough. [8]
Voxilaprevir is a hepatitis C virus (HCV) nonstructural (NS) protein 3/4A protease inhibitor (by Gilead) that is used in combination with sofosbuvir and velpatasvir. [2] The combination has the trade name Vosevi and received a positive opinion from the European Committee for Medicinal Products for Human Use in June 2017.
Grazoprevir is a second generation hepatitis C virus protease inhibitor acting at the NS3/4A protease targets. [3] It has good activity against a range of HCV genotype variants, including some that are resistant to most currently used antiviral medications. [4] [5]
It is a member of a class of antiviral drugs known as protease inhibitors. [3] Specifically, telaprevir inhibits the hepatitis C viral enzyme NS3/4A serine protease. [4] Telaprevir is only indicated for use against hepatitis C genotype 1 viral infections and has not been proven to be safe or effective when used for other genotypes of the virus.
Glecaprevir (INN, [1]) is a hepatitis C virus (HCV) nonstructural (NS) protein 3/4A protease inhibitor that was identified jointly by AbbVie and Enanta Pharmaceuticals. [2] It is being developed as a treatment of chronic hepatitis C infection in co-formulation with an HCV NS5A inhibitor pibrentasvir.